Analysts Set Karuna Therapeutics, Inc. PT at 267.80
KRTXDelisted Stock | USD 203.11 1.46 0.71% |
Slightly above 62% of Karuna Therapeutics' investor base is looking to short. The analysis of current outlook of investing in Karuna Therapeutics suggests that many traders are alarmed regarding Karuna Therapeutics' prospects. Karuna Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Karuna Therapeutics' earnings reports, geopolitical events, and overall market trends.
Karuna |
Karuna Therapeutics, Inc. has been given a consensus rating of Hold by the eighteen ratings firms that are covering the firm, Marketbeat.com reports. Ten analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1-year price target among brokers
Read at thelincolnianonline.com
Karuna Therapeutics Fundamental Analysis
We analyze Karuna Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Karuna Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Karuna Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Karuna Therapeutics is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Karuna Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Karuna Therapeutics stock to make a market-neutral strategy. Peer analysis of Karuna Therapeutics could also be used in its relative valuation, which is a method of valuing Karuna Therapeutics by comparing valuation metrics with similar companies.
Peers
Karuna Therapeutics Related Equities
TERN | Terns Pharmaceuticals | 3.41 | ||||
CYTK | Cytokinetics | 1.74 | ||||
EWTX | Edgewise Therapeutics | 1.33 | ||||
BPMC | Blueprint Medicines | 1.12 | ||||
DAWN | Day One | 1.81 | ||||
MREO | Mereo BioPharma | 2.20 | ||||
APLS | Apellis Pharmaceuticals | 2.23 | ||||
ABOS | Acumen Pharmaceuticals | 2.98 | ||||
AMLX | Amylyx Pharmaceuticals | 3.60 | ||||
DYN | Dyne Therapeutics | 3.79 | ||||
XFOR | X4 Pharmaceuticals | 5.13 | ||||
INZY | Inozyme Pharma | 6.09 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Other Consideration for investing in Karuna Stock
If you are still planning to invest in Karuna Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Karuna Therapeutics' history and understand the potential risks before investing.
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |